A Toxic Scandal Rocks Sri Lanka's Healthcare System: Was This Deadly Drug Cleared Too Easily?
A recent revelation by Dr. Chamal Sanjeewa, Chairman of the Doctors' Trade Union Alliance for Medical and Civil Rights, has sent shockwaves through Sri Lanka's healthcare sector. The controversial Ondansetron Injection, later found to contain a bacterial toxin, had reportedly passed laboratory testing before being imported into the country. But here's where it gets controversial: Dr. Sanjeewa claims the initial test results showed no signs of bacterial toxicity, raising serious questions about the reliability of the testing process and the integrity of the supply chain.
A Timeline of Troubling Events
Dr. Sanjeewa revealed that the injections, manufactured in India in 2024 and 2025, were imported into Sri Lanka in four separate batches during 2025. Each batch consisted of a staggering 67,600 vials, all of which were supposedly tested in Indian laboratories before shipment. The importing company assured the Drug Regulatory Authority that the drug met all necessary standards, including tests for pH value, appearance, composition, volume, antimicrobial activity, and crucially, bacterial toxicity.
The Indian Connection: A Matter of Trust?
The doctor emphasized that the company provided documentation confirming the drug’s compliance with European standards, which mandate bacterial toxin levels below 9.9 international units per milligram. However, the fact that the toxin was later detected in Sri Lanka casts doubt on the accuracy of these Indian test results. Dr. Sanjeewa warns that if the drug is cleared again based solely on Indian tests, it would severely damage public trust in Sri Lanka’s healthcare system.
A Systemic Failure?
This incident highlights a deeper issue: Sri Lanka’s Quality Control Laboratory, responsible for verifying such drugs, lacks accreditation from the Sri Lanka Accreditation Body (SLAB). Establishing a fully equipped, internationally accredited lab would cost approximately Rs. 5 billion—a sum Dr. Sanjeewa deems modest compared to other government expenditures. Without such a facility, substandard medicines could continue to slip through the cracks, endangering lives and wasting public funds.
Who’s to Blame?
Dr. Sanjeewa calls for legal action against the politicians and officials responsible for this debacle, arguing that their negligence has eroded public confidence in the health administration. And this is the part most people miss: the lack of accountability in such cases perpetuates a cycle of mistrust and inefficiency.
A Call to Action
The doctor urges the government to prioritize establishing a state-of-the-art testing facility to safeguard public health. Failure to do so, he warns, will not only risk more lives but also result in significant financial losses for the state.
What Do You Think?
Is Sri Lanka’s healthcare system in need of urgent reform? Should there be stricter oversight on imported medicines? And who should be held accountable for this scandal? Share your thoughts in the comments below—let’s spark a conversation that could drive real change.
